Stem cell marketing laws now exist in eight states, and six of them set the exact words your ads must carry. This reference gives you each state notice word for word, the type size rule, who each law covers and what it asks of your office. It ends with the one thing no state law can change: the federal status of exosome products.
TLDR: Stem cell marketing laws in Florida, Utah, Tennessee, Vermont, Washington and Georgia require a statutory notice in every ad, copied word for word. Florida has a second notice for podiatric physicians. California requires a posted and written notice. Wyoming has no notice wording but limits who may advertise. The notices differ, so one text cannot serve every state. No state law changes the federal status of an exosome product. Use this page as your copy source, then have counsel confirm.
Important Note This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. State laws change frequently and vary significantly. All state-specific marketing decisions should be reviewed by qualified legal counsel licensed in your state before implementation. Regen Portal is a marketing and consulting company, not a law firm.
Copy and paste is usually the lazy move in marketing. Here it is the right one.
A state stem cell notice is text the legislature wrote. Your designer cannot shorten it. Your copywriter cannot smooth it out. A notice that is close is not the notice. One mistake is easy to make: borrowing another state’s wording because it looks about the same.
This page gives each notice word for word, state by state. It also covers the type size rule, who each law reaches and what it asks of your office. If you want the short version first, read our overview of which states have passed stem cell laws.
How to Use This Reference
Find every state where you treat patients. Copy that state’s notice exactly. Set it at the size the law requires. Then add the office steps, such as a posted notice or a signed form.
Before a notice goes to print or into a paid ad, compare it with the statute itself. We link the official text where the state publishes it in a form we could check. Laws change, and your attorney should sign off on the final version.
What this means for your practice: Treat this page as a starting point for your copy, not the last word. The statute is the last word. Next comes the rule that trips up the most designers: size.
The Type Size Rule and the Office Rules
Most notice states care about size as much as wording. In Florida, Tennessee and Georgia, the notice must be clearly legible and no smaller than the largest type in the ad. If your headline is 48-point, the notice is 48-point.
Utah, Vermont and Washington use the same test for print ads. For other ads, such as radio or video, they also accept a notice that is clearly spoken. Check your state’s statute before you rely on a spoken notice.
Office posting is a separate rule. Utah, Vermont, Washington and California require the notice on paper at least 8.5 by 11 inches, in at least 40-point type, at the entrance and in an area patients can see. The Florida physician statute does not require an office posting.
The table puts the ad rule and the office steps side by side. Read it with the state sections below, which give the notice text.
| State | Notice in Ads | Office Steps |
|---|---|---|
| Florida physicians | Yes, no smaller than the largest type | Signed consent before treatment |
| Florida podiatric physicians | Yes, no smaller than the largest type | Signed consent before the procedure |
| Utah | Yes; print at full size, other ads legible or spoken | Written notice before therapy, 40-point posting, signed consent |
| Tennessee | Yes, no smaller than the largest type | Signed consent before therapy |
| Vermont | Yes; print at full size, other ads legible or spoken | Written notice before the first dose, 40-point posting, signed form each time the product is given |
| Washington | Yes; print at full size, other ads legible or spoken | 40-point posting, signed consent before each therapy |
| Georgia | Yes, no smaller than the largest type | Signed consent before therapy |
| California | Not in the statute (house policy: yes) | 40-point posting, written notice before the first therapy |
| Wyoming | No notice wording; advertise only if every condition is met | Written informed consent, including financial responsibility |
What this means for your practice: Your designer needs the size rule before the first draft, not after. A notice squeezed into a footer fails in Florida, Tennessee and Georgia even when every word is right.
The Six States With a Statutory Ad Notice
These six states wrote a notice into law and require it in every ad for the therapy. Here is each one, with who it covers and what else it asks. If you practice in Florida, Utah, Tennessee, Vermont, Washington or Georgia, the ad needs your state’s notice word for word.
Florida Physicians
Who it covers: Florida physicians who use stem cell therapy the FDA has not approved, within their scope of practice, in orthopedics, wound care or pain management. Osteopathic physicians have a matching section. What else it asks: products from an FDA-registered, accredited facility and a signed consent form before treatment. Read the Florida physician statute, s. 458.3245.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.
For the product rules and what the law leaves out, see our guide to Florida’s stem cell rules.
Florida Podiatric Physicians
Who it covers: podiatric physicians who use cellular or tissue-based products the FDA has not approved. The uses are connective tissue, ligament and tendon repair, wound care and pain management. It has been in effect since June 11, 2026. What else it asks: a signed consent form before the procedure. The podiatric statute, s. 461.011, uses the same type size rule as the physician law.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This podiatric physician performs procedures using cellular or tissue-based products that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any procedure using these products.
Do not swap the two Florida notices. A podiatry ad with the physician notice is wrong, and so is the reverse.
Utah: Utah Code 58-1-512
Who it covers: any health care provider whose scope of practice includes stem cell therapy. That is wider than a physician-only law. It also reaches suppliers. A company may supply cells or tissue products to a Utah provider only after the provider confirms in writing that each patient will get the notice. What else it asks: a written notice before the therapy, a 40-point office posting and a signed consent form. See the Utah stem cell disclosure statute.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing a stem cell therapy.
Tennessee: Public Chapter 1016
Who it covers: physicians who use stem cell or regenerative medicine therapy the FDA has not approved, within their scope of practice. It has been in effect since July 1, 2026, and it is not limited to orthopedics, pain or wound care. What else it asks: a signed consent form before therapy. Early summaries of this law carried notice wording that is not in the enacted text. Replace any older version with the text below.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW. This physician performs one (1) or more stem cell or regenerative medicine therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider before undergoing any stem cell or regenerative medicine therapy.
Vermont: 18 V.S.A. § 4502
Who it covers: clinicians who give patients “stem cell or stem cell-related products” the FDA has not approved. The Vermont definitions section names sources such as bone marrow, adipose tissue, amniotic membrane and placenta. It also reaches “intracellular or extracellular components or vesicles.”
What else it asks: a written notice before the first dose, a 40-point office posting and a signed disclosure form each time the product is given. The written notice must also tell patients how to file a complaint and how to reach the Attorney General’s Consumer Assistance Program. Read the Vermont notice statute.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER VERMONT LAW. This health care practitioner administers one or more stem cell or stem cell-related products that have not been approved by the U.S. Food and Drug Administration. You are encouraged to consult with your primary care provider prior to having an unapproved stem cell or stem cell-related product administered to you.
Washington: RCW 18.130.420
Who it covers: licensed health professionals who perform a stem cell therapy the FDA has not approved. What else it asks: a 40-point office posting and a signed consent form before each therapy. See Washington’s stem cell statute.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER WASHINGTON LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider prior to undergoing a stem cell therapy.
Georgia: O.C.G.A. § 43-34-49
Who it covers: physicians and their designees who perform human stem cell therapies the FDA has not approved. The notice itself says “this physician or his or her designee.” It has been in effect since July 1, 2026. What else it asks: a signed consent form before therapy. Georgia’s notice says “the FDA,” not the agency’s full name. Copy it as written.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER GEORGIA LAW. This physician or his or her designee performs one or more human stem cell therapies that have not yet been approved by the FDA. You are encouraged to consult with your primary care provider before undergoing any human stem cell therapy.
What this means for your practice: Line the six notices up and the differences jump out. Tennessee names regenerative medicine therapies. Vermont names stem cell-related products. Georgia uses “the FDA.” Each one is right only in its own state.
California: Business and Professions Code § 684
California’s law covers health care practitioners who perform a stem cell therapy the FDA has not approved. It requires the notice posted at the entrance and in an area patients can see, on 8.5 by 11 paper in at least 40-point type. It also requires the same notice in writing before the first therapy.
The statute does not require the notice in ads, and it does not require a signature. Our house policy is to carry the notice in California ads anyway. Treat that as policy, not law.
Older summaries got this wording wrong. The notice says “have not been approved,” with no “yet,” and it says “primary care physician.” Replace any older version.
THIS NOTICE MUST BE PROVIDED TO YOU UNDER CALIFORNIA LAW. This health care practitioner performs one or more stem cell therapies that have not been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care physician prior to undergoing a stem cell therapy.
Wyoming: SF 48 Has No Statutory Notice
Wyoming’s law has no notice wording. A clinic may advertise stem cell therapy under the act only if it meets every condition. The cells must be the patient’s own mesenchymal cells. The therapy needs IRB oversight or investigational status. The cells must be made under current good manufacturing practice. And the patient signs written consent that covers the therapy’s status and the patient’s financial responsibility.
We recommend a house disclosure for Wyoming ads. It tracks the consent terms. It is not statutory text, and it does not make a non-compliant clinic’s ad lawful. Here it is, labeled as house policy:
This physician performs stem cell therapies that have not been approved by the United States Food and Drug Administration. These therapies are investigational. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy. You will be required to sign a written informed consent acknowledging the investigational status and your financial responsibility for the cost of treatment.
Arizona, Texas and Nevada
Arizona has no notice law. A 2026 bill would have created one, and it was vetoed.
Texas has an investigational framework under HB 810, passed in 2017. It is not a clinic authorization, and it is not one of the notice laws on this page.
Nevada is not a stem cell notice state. If a summary lists Nevada, ask for the statute before you change an ad.
Where Exosomes Fit: No State Law Changes Their Federal Status
Here is the short answer. No state law changes the federal status of an exosome product. No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. The FDA’s public safety notice on exosome products explains its concern.
State notice laws are written around cells and tissues. Vermont’s definition is the broadest. It names “intracellular or extracellular components or vesicles,” and exosomes are extracellular vesicles. Ask counsel how that applies to any product you handle. A state duty never makes an exosome product lawful to market under federal law.
For every other state, whether a law reaches an exosome product is a question for counsel. The federal answer stays the same either way.
So exosome marketing stays education only. Teach the biology and state plainly that no exosome product is FDA approved. Skip service pages, consult offers and booking lines. Google Ads does not accept exosome therapy ads either. Our explainer on where exosomes stand legally goes deeper.
What this means for your practice: A state law can add a duty. It cannot remove a federal one. For exosomes, that means teaching the science and stating the status, nothing more.
The Federal Floor Under Every State Rule
Every state rule above sits on top of federal law. The FDA regulates the product. The FTC regulates the claim. The FTC’s health products guidance and the FDA’s tissue products page lay out the federal side.
A state notice never fixes a bad claim. An ad can carry a perfect Florida notice and still draw an FDA warning letter if it says the therapy treats or heals a condition. Our posts on marketing 361 products and FTC claims substantiation cover the federal layers.
One Ad, Many States
Your website is visible in all 50 states, so which state’s law applies? The state where the patient is treated is usually the main one. But an ad that names clinics in two notice states raises a real question, and counsel should answer it.
The careful default is simple. Each location runs its own state’s notice. A regional ad that names locations in more than one notice state carries each of those notices.
Picture a practice with one clinic in Tampa and one in Atlanta. It wants a single social ad for both. The Florida notice alone is not enough, because Georgia’s law has been in effect since July 1, 2026. So the ad carries both notices, each at full size, or the practice splits it into two ads, one per state. Its counsel signs off on the final version either way.
Note: This scenario is illustrative and does not reference any specific Regen Portal client.
Five Questions to Bring to Your Attorney
You do not need to become a lawyer. You need to ask the right questions. Bring these five to counsel licensed in your state.
- Which notice states do I treat patients in, and does every ad carry each notice word for word?
- Does my state require an office posting, a written notice or a signed form, and are mine current?
- Does my state medical board have advertising rules that go beyond the FTC minimum?
- Does my state’s privacy law reach my marketing data?
- What does my state’s consumer protection law say about health claims?
Each question maps to one layer of state law. The answers will be specific to your state, which is the point.
Frequently Asked Questions
Isn’t Federal Compliance Enough?
No. Federal rules are the floor. Eight states add stem cell notice or consent laws, and every state has consumer protection law. A clinic can pass a federal review and still fail a state rule.
Which States Require a Stem Cell Notice in Every Ad?
Florida, Utah, Tennessee, Vermont, Washington and Georgia. Florida has two notices, one for physicians and one for podiatric physicians. California requires a posted and written notice. Wyoming has no notice wording but limits who may advertise.
Can I Use One Notice for Every State?
No. Each state wrote its own wording. Tennessee names regenerative medicine therapies, Vermont names stem cell-related products, and Georgia says “the FDA.” California leaves out the word “yet.” Use each state’s text exactly.
How Big Does the Notice Need to Be?
In Florida, Tennessee and Georgia, the notice must be clearly legible and no smaller than the largest type in the ad. Utah, Vermont and Washington use the same rule for print and allow a clearly spoken notice in other ads. Office postings in Utah, Vermont, Washington and California need at least 40-point type on 8.5 by 11 paper.
Does California Require the Notice in Ads?
Not by statute. Business and Professions Code § 684 requires an office posting and a written notice before the first therapy. Our house policy is to carry it in California ads too.
Do State Stem Cell Laws Cover Exosomes?
No state law changes the federal status of an exosome product, and no exosome product is FDA approved for any use. Vermont’s definition is broad enough to raise the question there, so ask counsel. Exosome marketing stays education only.
If My Website Reaches Every State, Which Law Applies?
Usually the state where the patient is treated. Online reach complicates it, so ask counsel how your treatment footprint affects your exposure. Each location should run its own state’s notice.
Who Is More Likely to Contact a Small Clinic, the FTC or My State?
For a single-location clinic, a state attorney general or medical board can be the more likely first contact. Any clinic can still receive a federal warning letter. Our post on what an FDA warning letter means covers that side. The HHS Office of Inspector General’s provider compliance training covers federal fraud rules.
Does My State Privacy Law Affect My Marketing?
It can. State privacy laws can govern how you collect and use marketing data. That sits alongside HIPAA, which the HHS HIPAA overview describes. Our HIPAA marketing guide covers the federal privacy layer, and counsel can address your state law.
Key Takeaways
- Six states want their notice in every stem cell ad, word for word: Florida, Utah, Tennessee, Vermont, Washington and Georgia.
- Florida has two notices. The podiatric notice has been in effect since June 11, 2026.
- The notices differ. Copy each state’s text exactly and compare it with the statute before print.
- Florida, Tennessee and Georgia want the notice no smaller than the largest type in the ad. Utah, Vermont and Washington use the same rule for print.
- California requires a posted and written notice. Carrying it in ads is house policy.
- Wyoming has no notice wording. A clinic may advertise under its act only when it meets every condition.
- No state law changes the federal status of an exosome product. Exosome marketing stays education only.
- Bring the five state law questions to counsel licensed in your state before you publish.
Close The State Law Gap
PS: Federal compliance is necessary but not sufficient, state law is the layer that catches what the FTC and FDA don’t. If your practice operates in a state with active enforcement posture, a state-specific marketing compliance review is worth the time. Reach out at hello@regenportal.com, or subscribe for regen compliance updates on YouTube at https://www.youtube.com/@oatellez.
Compliance Disclaimer This article is educational and does not constitute legal, medical, or regulatory advice. It reflects publicly available information that can change as regulations, enforcement priorities, and platform policies evolve. It does not promise any marketing outcome or specific compliance result. Before acting on anything here, have your own marketing reviewed by qualified legal counsel familiar with FDA, FTC, HIPAA, and the advertising rules in your state.
About Regen Portal: Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About Oscar Tellez: Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
